Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

References

• GrallaRJOsobaDKrisMGRecommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical OncologyJ Clin Oncol19991792971299410561376
   PubMed Web of Science ®Google Scholar
• RoilaFHeskethPJHerrstedtJPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnn Oncol2006171202816314401
   PubMed Web of Science ®Google Scholar
• Ihbe-HeffingerAEhlkenBBernardRThe impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization, and costs in German cancer centersAnn Oncol200415352653614998860
   PubMed Web of Science ®Google Scholar
• StewartDJDahrougeSCoyleDEvansWKCosts of treating and preventing nausea and vomiting in patients receiving chemotherapyJ Clin Oncol199917134435110458253
   PubMed Web of Science ®Google Scholar
• SykesAJKiltieAEStewartALOndansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomized study to assess efficacy, cost effectiveness, and quality of life following single-fraction radiotherapySupport Care Cancer1997565005039406364
   PubMed Web of Science ®Google Scholar
• Tina ShihYCXuYEltingLSCosts of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapyCancer2007110367868517567835
   PubMed Web of Science ®Google Scholar
• VanscoyGJFortnerBSmithRWeberRRihnTLPreventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemeticsCommunity Oncology200522127132
   Google Scholar
• HeskethPJSanz-AltamiraPBusheyJHeskethAMProspective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapySupport Care Cancer20122051043104721553313
   PubMed Web of Science ®Google Scholar
• RubensteinEBPalonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomitingClin Adv Hematol Oncol20042528428916163194
   PubMedGoogle Scholar
• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• KrautLFauserAAAntiemetics for cancer chemotherapy-induced emesis: potential of alternative delivery systemsDrugs200161111553156211577793
   PubMed Web of Science ®Google Scholar
• MasonJ WSelnessDSMoonTEO’MahonyBDonachiePHowellJPharmacokinetics and repolarization effects of intravenous and transdermal granisetronClin Cancer Res201218102913292122452942
   PubMed Web of Science ®Google Scholar
• Drug safety communication: updated information on 32 mg intravenous ondansetron (Zofran) dose and premixed ondansetron productsSilver Spring, MDUS Food and Drug Administration2012 [cited December 30, 2012] Available from: http://www.fda.gov/Drugs/DrugSafety/ucm330049.htmAccessed February 12, 2013
   Google Scholar
• GrossmanJCaspiASancuso® Granisetron transdermal delivery system: a formulation for chemotherapy-induced nausea and vomitingP&T Product Profiler2011362130
   Google Scholar
• Intravenous Kytril. [package insert]Basel, SwitzerlandRoche LaboratoriesInc1998–2005
   Google Scholar
• Oral Kytril. [package insert]Basel, SwitzerlandRoche Laboratories Inc2009
   Google Scholar
• HowellJSmeetsJDrenthHJGillDPharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomitingJ Oncol Pharm Pract200915422323119304880
   PubMedGoogle Scholar
• HowellJClarkGYellowleesAGutierrez-EsteinouREfficacy, safety, and tolerability of a transdermal granisetron patch for preventionof single-dose chemotherapy-induced nausea and vomiting: phase II trial resultsJ Oncol Pharm Pract200915Suppl 220
   Google Scholar
• HowellJYellowleesAGutierrez-EsteinouREfficacy, safety and tolerability of transdermal granisetron patch for prevention of multiday chemotherapy-induced nausea and vomiting: phase III trial resultsJ Support Oncol20086335 (abstract)
   Google Scholar
• PatelDChaudharySAParmarBBhuraNTransdermal drug delivery system: a reviewThe Pharma Innovation2012146675
   Google Scholar
• WokovichAMProdduturiSDoubWHHussainASBuhseLFTransdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy, and quality attributeEur J Pharm Biopharm20066411816797171
   PubMed Web of Science ®Google Scholar
• BocciaRVGordanLNClarkGHowellJDGrunbergSMEfficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multiday chemotherapy: a randomized, double-blind, phase III studySupport Care Cancer201119101609161720835873
   PubMed Web of Science ®Google Scholar
• GutschkeEBrachtSNagelSWeitschiesWAdhesion testing of transdermal matrix patches with a probe tack test – in vitro and in vivo evaluationEur J Pharm Biopharm201075339940420350598
   PubMed Web of Science ®Google Scholar
• Drug safety communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2010 [cited Dec 17]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm#safety_announcementAccessed February 12, 2013
   Google Scholar
• IV dolasetron withdrawal letter Available from: http://www.healthy-canadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14633a-eng.phpAccessed February 12, 2013
   Google Scholar
• Drug safety communication: New information regarding QT prolongation with ondansetron (Zofran). [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration6292012 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm310190.htmAccessed February 12, 2013
   Google Scholar
• DailyMed. Palonsetron prescribing informationUS National Library of Medicine2008 Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4216772-6c37-4ff0-a575-f758390656e3Accessed February 12, 2013
   Google Scholar
• Kytril (granisetron hydrochloride) injection, tablets and oral solution [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2009 [cited October 21, 2009]. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm187526.htmAccessed February 12, 2013
   Google Scholar
• NagelCIBackesFJHadeEMEffect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerGynecol Oncol2012124222122422055764
   PubMed Web of Science ®Google Scholar
• KuryshevYABrownAMWangLBenedictCRRampeDInteractions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channelsJ Pharmacol Exp Ther2000295261462011046096
   PubMed Web of Science ®Google Scholar
• GurpideASadabaBMartin-AlgarraSRandomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapyOncologist20071291151115517914085
   PubMed Web of Science ®Google Scholar